News

In the UK, venous thrombosis or blood clotting is a major cause of death and for those patients that survive PE and DVT, there can be long term

The approval was based on demonstration of improved progression-free survival (PFS) in a 96-week Phase III trial called CLARINET. The multi-center, international, randomized, double-blind, placebo-controlled trial enrolled a

Backed by funding of €15.1m from the European Commission (EC), the new consortium includes GSK and research partners from University of Oxford, Centre Hospitalier Universitaire Vaudois in Lausanne

Signifor LAR is a somatostatin analog (SSA) administered intramuscularly once-monthly, which exerts its pharmacological activity through binding to somatostatin receptors (SSTRs). Novartis Oncology president Bruno Strigini said: "The

ESUS occurs when a blood clot from somewhere in the body blocks a blood vessel in the brain and the source of this blood clot is unknown. In

The submission is based on results from Phase III trial, which evaluated the safety, tolerability and efficacy of Xtampza ER compared with placebo in opioid-experienced and opioid-naïve subjects

Injectafer was approved by the U.S. Food and Drug Administration (FDA) on July 25, 2013 for the treatment of IDA in adult patients who have intolerance to oral

On Monday, December 15, Judge Robert Sweet of the United States District Court for the Southern District of New York (New York City) issued a preliminary injunction requiring

As previously disclosed, PALOMA-1 achieved its primary endpoint with the combination of palbociclib and letrozole significantly prolonging progression-free survival (PFS) compared with letrozole alone in post-menopausal women with